These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities. Weinkove R; George P; Ruka M; Haira TH; Giunti G N Z Med J; 2021 Sep; 134(1542):96-108. PubMed ID: 34531588 [TBL] [Abstract][Full Text] [Related]
23. Reactions Related to CAR-T Cell Therapy. Miao L; Zhang Z; Ren Z; Li Y Front Immunol; 2021; 12():663201. PubMed ID: 33995389 [TBL] [Abstract][Full Text] [Related]
24. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions. Hunter BD; Jacobson CA J Natl Cancer Inst; 2019 Jul; 111(7):646-654. PubMed ID: 30753567 [TBL] [Abstract][Full Text] [Related]
27. Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. Suarez Montero JC; Caballero Gonzalez AC; Martín Aguilar L; Mancebo Cortés J Med Intensiva (Engl Ed); 2022 Apr; 46(4):201-212. PubMed ID: 35216966 [TBL] [Abstract][Full Text] [Related]
28. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789 [TBL] [Abstract][Full Text] [Related]
29. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score. Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009 [TBL] [Abstract][Full Text] [Related]
30. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Hay KA Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609 [TBL] [Abstract][Full Text] [Related]
31. [Practical aspects of the application of CAR T cells and management of their toxicities]. Bücklein V; Blumenberg V; Subklewe M Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189 [TBL] [Abstract][Full Text] [Related]
34. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993 [TBL] [Abstract][Full Text] [Related]
35. Critical care management of chimeric antigen receptor T-cell therapy recipients. Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616 [TBL] [Abstract][Full Text] [Related]
36. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302 [TBL] [Abstract][Full Text] [Related]
37. The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Zhang Q; Zhu X; Xiao Y Ann Hematol; 2024 Jul; 103(7):2197-2206. PubMed ID: 38329486 [TBL] [Abstract][Full Text] [Related]
38. Cytokines in CAR T Cell-Associated Neurotoxicity. Gust J; Ponce R; Liles WC; Garden GA; Turtle CJ Front Immunol; 2020; 11():577027. PubMed ID: 33391257 [TBL] [Abstract][Full Text] [Related]
39. Use of long-term corticosteroids in patients treated with CAR T-cell therapy. Hashmi H; McGann M; Greenwell BI J Oncol Pharm Pract; 2023 Mar; 29(2):473-476. PubMed ID: 35635259 [TBL] [Abstract][Full Text] [Related]
40. Toxicities following CAR-T therapy for hematological malignancies. Hernani R; Benzaquén A; Solano C Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]